High purity Livagen/Lys-Glu-Asp-Ala with good quality

• FOXO4-DRI is a peptide antagonist designed to interfere with the interaction of FOXO4 and p53. Disruption of the p53-FOXO4 interaction causes p53 to be excluded from the nucleus and directed to mitochondria to induce apoptosis in senescent cells, ultimately eliminating senescent fibroblasts by triggering apoptosis.

  
  

1. Senescent Cell Clearance: Research suggests that senescent cells accumulate in the body with age and contribute to age-related decline and diseases. FOXO4-DRI is designed to selectively target and induce the death of these senescent cells while sparing healthy cells. By promoting the clearance of senescent cells, it aims to potentially mitigate age-related conditions.

   Preclinical Studies: Studies conducted in animal models have shown promising results regarding the clearance of senescent cells and potential health benefits associated with reduced senescent cell burden. These studies have indicated improvements in various age-related conditions and tissue function.

   Experimental Nature: Despite its potential benefits in preclinical studies, the use of FOXO4-DRI remains largely experimental. Comprehensive human studies regarding its safety, efficacy, and long-term effects are limited.

   Safety and Efficacy in Humans: As of now, the safety profile and potential side effects of FOXO4-DRI in humans are not well-established due to the lack of comprehensive human trials. There's a need for further research to evaluate its safety, optimal dosage, and potential applications in human health.

   
   

    

Wuhan Comings Biotechnology Co., Ltd.is a company specializing in the production of FOXO4-DRI peptide raw materials. We have our own laboratory and production workshop. Committed to providing high-purity raw materials and excellent customer service, we sincerely hope to cooperate with you.